VantAI is a biotechnology company based in New York, founded in 2019. It specializes in generative AI-enabled drug discovery, focusing on making protein interactions programmable to advance medicine. The company employs advanced computational biology, machine learning, and structural proteomics to accelerate the design and discovery of novel therapeutics, including biologics and small-molecule drugs.

VantAI's integrated discovery platform features three key technologies: NeoLink, a high-throughput structural proteomics platform; Neo-1, an AI model that generates small molecules to stabilize protein interactions; and a phase-shifting technology for proximity modulators. This platform models complex protein-protein interactions to identify new molecular entities and predict drug profiles, significantly reducing development time and costs.

VantAI collaborates with pharmaceutical companies and research institutions, including notable partnerships with Janssen, Bristol Myers Squibb, and Halda Therapeutics. The company aims to unlock new therapeutic possibilities and enable next-generation medicines across various diseases.